News & Events

Press Releases

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Events

11th Annual Tumor Models Conference

Jul 12 - Jul 13

Listen to Webcast

EHA 2023 Hybrid Congress

Jun 8 - Jun 11

https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ Frankfurt, Germany + Google Map

BIO International Convention

Jun 5 - Jun 7

Listen to Webcast

AACR ANNUAL MEETING 2023

Apr 14 - Apr 19

In the News

Precision Medicine Online

Salarius Pharmaceuticals Cleared to Begin Phase I Trial of SP-3164 in Non-Hodgkin Lymphoma

Global Newswire

Salarius Expands Oncology Pipeline Through Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

The Clinical Trials Guru

David Arthur, Salarius CEO Speaks with Dan Sfera of The Clinical Trials Guru

Houston Business Journal

Salarius Pharmaceuticals raises millions for expanded clinical trial, moves office in TMC

15 Biotech Companies in Houston Making a Major Impact on Medicine

Empowered Patient Podcast

Targeting Epigenetic Causes of Ewing’s Sarcoma with David Arthur Salarius Pharmaceuticals on Empowered Patient Podcast with Karen Jagoda